Biochemical recurrence of pathological T2+ localized prostate cancer after robotic-assisted radical prostatectomy: A 10-year surveillance

Table 2 Brief conclusions of pT2+ from the past published literature

	Year	Sample size	Surgical method	PSA level (ng/mL)	Clinical TNM stage	Pathology Gleason group	BCR rate
Freedland et al[1]	2003	Retrospective, 214 men, SEARCH Database	RP (no mention of open RP or RARP)	Mean: 10.5 ± 8.6, median: 8.0	T1: 97 (46%); T2: 110 (53%); T3: 3 (1%)	1: 105 (51%); 2 and 3: 89 (43%); 4 and 5: 14 (7%)	6-yr BCR rate 50%
Leite et al[19]	2014	Retrospective, 58 men	Open RP	N/M	N/M	N/M	Mean follow-up: 35.9 ± 23.1 mo; BCR rate: 31%
Hashimoto et al[12]	2015	Retrospective, 837 men	RARP	6.90, range: 3-47.4	T1c: 634 (75.7%); T2a: 111 (13.3%); T2b: 46 (5.5%); T2c: 39 (4.7%); T3: 7 (0.8%)	1: 65 (7.8%); 2: 377 (45%); 3: 230 (26.2%); 4 and 5: 165 (19.7%)	5-yr BCR free-survival: 62.4%
Karl et al[13]	2015	Retrospective, 956 men	Retropubic RP: 88%; Laparoscopic RP: 6%; RARP: 4%; Perineal RP: 3%	< 4: 13%; 4-9.9: 65%; 10-19.9: 18%; ≥ 20: 4%	N/M	1: 39%; 2: 52%; 3: 7%; 4 and 5: 2%	Mean follow-up: 48 mo; BCR rate: 25.4%

SEARCH: Shared Equal Access Regional Cancer Hospital; N/M^: Not mentioned; BCR: Biochemical recurrence; TNM: Tumor-Node-Metastasis; PSA: Prostate specific antigen; RARP: Robotic-assisted radical prostatectomy; RP: Radical prostatectomy.